Dogwood Therapeutics, INC. (DWTX) — SEC Filings

Overview

Dogwood Therapeutics, INC. (DWTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 26, 2026: Dogwood Therapeutics, Inc. filed an 8-K on March 26, 2026, under Item 7.01, Regulation FD Disclosure, indicating they are making a public announcement of material non-public information. This filing suggests the company is proactively sharing important news, likely to ensure fair and broad dissemina

Sentiment Summary

Across 42 filings, the sentiment breakdown is: 1 bullish, 5 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Dogwood Therapeutics, INC. is neutral.

Filing Type Overview

Dogwood Therapeutics, INC. (DWTX) has filed 25 8-K, 6 10-Q, 4 DEF 14A, 1 DEFA14A, 2 10-K, 1 8-K/A, 1 SC 13D, 1 10-K/A, 1 SC 13G/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (42)

• Dogwood Therapeutics Files 8-K: Regulation FD Disclosure — 8-K · Mar 26, 2026
  Dogwood Therapeutics, Inc. filed an 8-K on March 26, 2026, under Item 7.01, Regulation FD Disclosure, indicating they are making a public announcement of materi
• 8-K Filing — 8-K · Nov 28, 2025
• 8-K Filing — 8-K · Nov 21, 2025
• Dogwood Therapeutics' Losses Soar Amid R&D Surge, Going Concern Doubt Looms — 10-Q · Nov 7, 2025 Risk: high
  Dogwood Therapeutics, Inc. (DWTX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $30,476,921, a substantial
• 8-K Filing — 8-K · Nov 6, 2025
• DWTX Seeks Shareholder Nod for Preferred Stock Conversion, Equity Plan — DEF 14A · Oct 20, 2025 Risk: medium
  Dogwood Therapeutics, Inc. (DWTX) is holding a Special Meeting on November 21, 2025, to seek stockholder approval for several key proposals related to its recen
• Dogwood Therapeutics Files DEFA14A — DEFA14A · Oct 9, 2025 Risk: low
  Dogwood Therapeutics, Inc. filed a DEFA14A on October 9, 2025, reporting its corporate actions. The company, formerly known as Virios Therapeutics, Inc., is inc
• Dogwood Therapeutics Files 8-K on Key Corporate Events — 8-K · Sep 29, 2025 Risk: medium
  On September 29, 2025, Dogwood Therapeutics, Inc. filed an 8-K report detailing several material events. These include entering into a material definitive agree
• Dogwood's Losses Soar Amid R&D Surge, Going Concern Doubts Emerge — 10-Q · Aug 13, 2025 Risk: high
  Dogwood Therapeutics, Inc. (DWTX) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $14,732,305, a substantial rise f
• Dogwood Therapeutics Announces Director and Officer Changes — 8-K · Jul 2, 2025 Risk: medium
  Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed an 8-K on July 2, 2025, reporting changes effective June 27, 2025. The filing details the
• Dogwood Therapeutics Files 8-K: Board & Compensation Updates — 8-K · Jun 24, 2025 Risk: medium
  Dogwood Therapeutics, Inc. announced on June 18, 2025, a change in its board of directors and executive compensation arrangements. The company also filed financ
• Dogwood Therapeutics Files Q1 2025 10-Q — 10-Q · May 9, 2025 Risk: medium
  Dogwood Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Virios Therapeutics, Inc., reported financial data for its
• Dogwood Therapeutics Files 8-K on Financials — 8-K · May 8, 2025 Risk: low
  Dogwood Therapeutics, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing also includes financial state
• Dogwood Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 30, 2025 Risk: low
  Dogwood Therapeutics, Inc. filed its definitive proxy statement on April 30, 2025, for its annual meeting on June 18, 2025. The company, formerly known as Virio
• Dogwood Therapeutics Files 8-K with Exhibits — 8-K · Apr 3, 2025 Risk: low
  On April 3, 2025, Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed an 8-K report. The filing primarily concerns financial statements and ex
• Dogwood Therapeutics Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  Dogwood Therapeutics, Inc. filed its 2024 10-K on March 31, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company,
• Dogwood Therapeutics Enters Material Definitive Agreement — 8-K · Mar 14, 2025 Risk: medium
  On March 12, 2025, Dogwood Therapeutics, Inc. entered into a material definitive agreement. The company, formerly known as Virios Therapeutics, Inc., is a pharm
• Dogwood Therapeutics Files 8-K with Key Corporate Updates — 8-K · Mar 12, 2025 Risk: medium
  On March 12, 2025, Dogwood Therapeutics, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreem
• Dogwood Therapeutics Files 8-K/A Amendment — 8-K/A · Dec 18, 2024 Risk: medium
  Dogwood Therapeutics, Inc. filed an 8-K/A amendment on December 18, 2024, related to events on October 4, 2024. The filing primarily concerns financial statemen
• Dogwood Therapeutics Faces Delisting Concerns — 8-K · Nov 21, 2024 Risk: high
  Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed an 8-K on November 21, 2024, reporting a notice of delisting or failure to satisfy a conti
• Dogwood Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 8, 2024 Risk: medium
  Dogwood Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Virios Therapeutics, Inc., is in the pharmace
• Dogwood Therapeutics Files 8-K on Financials — 8-K · Nov 7, 2024 Risk: low
  Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition
• Dogwood Therapeutics Files 8-K — 8-K · Oct 30, 2024 Risk: low
  Dogwood Therapeutics, Inc. filed an 8-K on October 30, 2024, reporting on events and financial statements as of October 29, 2024. The company, formerly known as
• CK Life Sciences Discloses Stake in Virios Therapeutics — SC 13D · Oct 15, 2024 Risk: medium
  CK Life Sciences Int'l., (Holdings) Inc. has filed a Schedule 13D regarding Virios Therapeutics, Inc. The filing, dated October 15, 2024, indicates a change in
• Virios Therapeutics Acquires 03 Life Sciences — 8-K · Oct 7, 2024 Risk: medium
  Virios Therapeutics, Inc. announced on October 4, 2024, the completion of its acquisition of 03 Life Sciences, a company focused on developing novel treatments
• Virios Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  Virios Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, incorporated in Delaware, is in the pharmaceutical preparations indus
• Virios Therapeutics Files 8-K — 8-K · Aug 8, 2024 Risk: low
  Virios Therapeutics, Inc. filed an 8-K on August 8, 2024, to report on its results of operations and financial condition, and to file financial statements and e
• Virios Therapeutics Reports on Shareholder Vote — 8-K · Jun 20, 2024 Risk: low
  Virios Therapeutics, Inc. filed an 8-K on June 20, 2024, reporting on a matter submitted to a vote of security holders on June 18, 2024. The filing details the
• Virios Therapeutics Faces Delisting Notice — 8-K · Jun 12, 2024 Risk: high
  Virios Therapeutics, Inc. filed an 8-K on June 12, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is based in
• Virios Therapeutics Enters Material Definitive Agreement — 8-K · May 20, 2024 Risk: medium
  Virios Therapeutics, Inc. announced on May 19, 2024, that it entered into a Material Definitive Agreement. The company, incorporated in Delaware with its princi
• Virios Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  Virios Therapeutics, Inc. (DWTX) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Virios Therapeutics, Inc. filed a 10-Q report for the period endi
• Virios Therapeutics Files 8-K on Financials — 8-K · May 9, 2024 Risk: low
  Virios Therapeutics, Inc. filed an 8-K on May 9, 2024, to report on its results of operations and financial condition. The filing also includes financial statem
• Virios Therapeutics Faces Delisting Concerns — 8-K · May 7, 2024 Risk: high
  Virios Therapeutics, Inc. filed an 8-K on May 7, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, incorporated
• Virios Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 25, 2024 Risk:
  Virios Therapeutics, Inc. (DWTX) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. The 2024 Annual Meeting of Stockholders for Virios Therapeuti
• Virios Therapeutics Files 10-K/A Amendment — 10-K/A · Mar 8, 2024 Risk:
  Virios Therapeutics, Inc. (DWTX) filed a Amended Annual Report (10-K/A) with the SEC on March 8, 2024. Virios Therapeutics, Inc. filed a 10-K/A amendment on Mar
• Virios Therapeutics Files 8-K on Security Holder Vote — 8-K · Mar 6, 2024 Risk: low
  Virios Therapeutics, Inc. filed an 8-K on March 6, 2024, reporting on a matter submitted to a vote of security holders as of March 1, 2024. The filing does not
• Virios Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 1, 2024 Risk: medium
  Virios Therapeutics, Inc. (DWTX) filed a Annual Report (10-K) with the SEC on March 1, 2024. Virios Therapeutics, Inc. filed its 2023 annual report on Form 10-K
• Virios Therapeutics Files 8-K on Financials — 8-K · Feb 29, 2024 Risk: low
  Virios Therapeutics, Inc. filed an 8-K on February 29, 2024, reporting on its results of operations and financial condition. The filing details the company's st
• Virios Therapeutics Reports Officer/Director Changes, Compensation — 8-K · Feb 27, 2024 Risk: medium
  Virios Therapeutics, Inc. filed an 8-K on February 27, 2024, reporting events that occurred on February 26, 2024. The filing indicates changes related to the de
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Virios Therapeutics seeks shareholder approval for a reverse stock split to fund Phase 2 development of IMC-2 for Long-COVID. — DEF 14A · Feb 2, 2024 Risk:
  Virios Therapeutics, Inc. (DWTX) filed a Proxy Statement (DEF 14A) with the SEC on February 2, 2024. Virios Therapeutics plans to advance its development candid
• Virios Therapeutics Files Administrative 8-K; No New Material Events — 8-K · Jan 3, 2024
  Virios Therapeutics, Inc. filed an 8-K on January 3, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded compa

Risk Profile

Risk Assessment: Of DWTX's 33 recent filings, 5 were flagged as high-risk, 16 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Dogwood Therapeutics, INC.'s most recent 10-Q filing (Nov 7, 2025):

• Revenue: $0
• Net Income: -$30,476,921
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $10,126,710
• Operating Margin: N/A
• Total Assets: $91,992,613
• Total Debt: $0

Key Executives

• Greg Duncan
• Angela Walsh
• Cindy Chiu

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Dogwood Therapeutics are focused on developing novel therapies, often requiring substantial capital investment before any revenue can be generated. The competitive landscape is intense, with many companies vying for breakthroughs in similar therapeutic areas.

Top Tags

pharmaceuticals (7) · corporate-governance (5) · corporate-action (4) · 10-Q (4) · financials (4) · Virios Therapeutics (4) · financial-reporting (3) · company-update (3) · delisting (3) · compliance (3)

Key Numbers

• Net Loss: $30,476,921 — for the nine months ended September 30, 2025, up from $4,621,852 in 2024
• Research and Development Expenses: $19,528,283 — for the nine months ended September 30, 2025, up from $1,214,964 in 2024
• Loss on Debt Conversion: $6,134,120 — with related party for the nine months ended September 30, 2025
• Cash: $10,126,710 — as of September 30, 2025, down from $14,847,949 at December 31, 2024
• Accumulated Deficit: $104,295,867 — as of September 30, 2025
• Net Proceeds from Offering: $4,252,245 — from March 2025 registered direct offering of common stock
• Debt Converted: $19,500,000 — principal amount of loan converted into Series A-1 Preferred Stock
• Common Stock Shares Outstanding: 2,293,162 — as of November 5, 2025
• Revenue: 0 — for the three and nine months ended September 30, 2025 and 2024
• Net Cash Used in Operating Activities: $11,981,464 — for the nine months ended September 30, 2025
• Series A Preferred Stock Shares: 2,269.1494 — Outstanding, non-voting, subject to conversion approval.
• Series A-1 Preferred Stock Shares: 284.2638 — Outstanding, non-voting, subject to conversion approval.
• Series A-2 Preferred Stock Shares: 190.0572 — Outstanding, non-voting, subject to conversion approval.
• Common Stock Shares Excluded from Proposal 1 Vote: 211,951 — Not entitled to vote on Proposal No. 1 per Nasdaq rules.
• Common Stock Shares Excluded from Proposal 3 Vote: 382,034 — Not entitled to vote on Proposal No. 3 per Nasdaq rules.

Related Companies

VIRI

Frequently Asked Questions